基因编辑公司Intellia Therapeutics(NTLA)今日盘中股价大跌5.8%,引起了市场的广泛关注。
根据报道,这次股价下跌与多家投资银行对Intellia Therapeutics投资评级和目标价进行下调有关。其中,摩根士丹利将该公司的评级从"增持"下调至"中性",并将目标股价由45美元大幅下调至13美元。此外,摩根大通也将该公司的投资评级从"增持"下调至"中性"。
作为一家处于发展期的基因编辑科技公司,Intellia Therapeutics产品线仍待丰富,商业化前景存有不确定性。分析人士普遍对该公司发展前景持谨慎态度,并下调投资评级及目标价来反映他们对公司长期价值的重新评估。这直接打击了市场对NTLA未来前景的预期,推动当天公司股价出现大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.